Market revenue in 2023 | USD 224.1 million |
Market revenue in 2030 | USD 341.5 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Product registration & clinical trial applications |
Fastest growing segment | Legal representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory consulting, Legal representation, Regulatory writing & publishing, Product registration & clinical trial applications, Regulatory Submissions, Regulatory Operations, Other services |
Key market players worldwide | Genpact Ltd, Criterium Inc., Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, Labcorp Drug Development, FREYR Battery Inc, Cencora Inc, Pharmexon, QVigilance, BlueReg Group, ZEINCRO Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs outsourcing market will help companies and investors design strategic landscapes.
Product registration & clinical trial applications was the largest segment with a revenue share of 25.97% in 2023. Horizon Databook has segmented the France regulatory affairs outsourcing market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, other services covering the revenue growth of each sub-segment from 2018 to 2030.
France is among the top eight pharmaceutical markets worldwide in terms of market size. Pharmaceutical companies have been rapidly growing in France over the last few decades. For instance, in 2018, approximately 400 drug candidates were in clinical development phase, with R&D investments of around 10.2 million.
\Such investments by these companies simultaneously boost the demand for regulatory services. France is a highly regulated market and the rate of generic penetration is low, which indirectly emphasizes the need for innovative drugs, thereby facilitating clinical trials and R&D projects in the country, which is leading to market growth.
As of 2016, France was ranked third among the EU nations and sixth across the world in terms of economy, which highlights the market attractiveness. Furthermore, supportive government initiatives such as Choose France event that showcases the country’s economic appeal & encourages foreign investments in the country are anticipated to boost the manufacturing and commercialization activities in the country, which in turn is expected to boost market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France regulatory affairs outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into France regulatory affairs outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account